Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1471-1478

  Hara, Masayasu ^a,b   Nakanishi, Hayao ^a   Tsujimura, Kunio ^c   Matsui, Makoto ^a   Yatabe, Yasushi ^a   Manabe, Tadao ^b   Tatematsu, Masae ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHROMIUM 51 RELEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; G(M1) GANGLIOSIDE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 44449108782     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00821.x     Document Type: Article

References (41)

1. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.
2. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26: 3661-78.
3. Galizia G, Lieto E, De Vita F et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26: 3654-60.
4. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9-15.
5. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669-72.
6. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7.
7. Tokunaga A, Onda M, Okuda T et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75: 1418-25.
8. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
9. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
10. Yokoyama H, Ikehara Y, Kodera Y et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006; 95: 1504-13.
11. Doi T, Koizumi W, Siena S et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003; 22: Abstract 1036.
12. Barnett D, Stevens A, Longson C. Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK. Lancet Oncol 2006; 7: 807-8.
13. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006; 25: 525-35.
14. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-99.
15. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39 (Suppl. C): 1-16.
16. Carson WE, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001; 31: 3016-25.
17. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia, 2nd edn. Br J Cancer 1998; 77: 1-10.
18. Nakanishi H, Yasui K, Ikehara Y et al. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clin Exp Metastasis 2005; 22: 137-47.
19. Nakanishi H, Mochizuki Y, Kodera Y et al. Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci 2003; 94: 112-18.
20. Niwa T, Ikehara Y, Nakanishi H et al. Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation. J Histochem Cytochem 2005; 53: 75-85.
21. Versteeg HH, Niijhuis E, van den Brink GR et al. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 2000; 350: 717-722.
22. Ohashi N, Kodera Y, Nakanishi H et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005; 27: 637-44.
23. Nakanishi H, Ito S, Mochizuki Y, Tatematsu M. Evaluation of Chemosensitivity of Micrometastases with Green Fluorescent Protein-Tagged Tumor Models in Mice. Totowa, NJ: Humana Press, 2005.
24. Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl. 4): S3-8.
25. Mimori K, Nagahara H, Sudo T et al. The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. J Surg Oncol 2006; 93: 44-6.
26. Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: Current status of matuzumab and panitumumab. Clin Cancer Res 2007; 13: S4597-601.
27. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
28. Dickler HB, Kunkel HG. Interaction of aggregated-globulin with B lymphocytes. J Exp Med 1972; 136: 191-6.
29. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9: 457-92.
30. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25: 158-64.
31. Bellone S, Frera G, Landolfi G et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007; 106: 513-20.
32. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998; 46: 318-26.
33. Eisenbeis CF, Grainger A, Fischer B et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin Cancer Res 2004; 10: 6101-10.
34. Parihar R, Nadella P, Lewis A et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 2004; 10: 5027-37.
35. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006; 66: 517-26.
36. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
37. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
38. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901.
39. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-86.
40. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80.
41. Hirata A, Hosoi F, Miyagawa M et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005; 65: 4253-60.